SAGE PRO

Home / Research / Fortis Healthcare Limited

SAGE PRO · ORIGINAL EQUITY RESEARCH

Fortis Healthcare Limited — Q2 FY27 Results Analysis

Group revenue increased 17.3%

Published · Quarter Q2 FY27 · FORTIS

PeriodQ2 FY27
COMPANY-SPECIFIC GRAPHICAL SUMMARY

What the reported figures reveal

CHART 1

Q2 group revenue

Q2 FY26 implied₹2,332 crore
Q2 FY27₹2,735 crore

https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6c319faf-8b70-4c0b-99a7-4a47186e08db.pdf

CHART 2

Operating EBITDA pre-ESOP

Q2 FY26 implied₹556 crore
Q2 FY27₹663 crore

https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6c319faf-8b70-4c0b-99a7-4a47186e08db.pdf

CHART 3

Group operating EBITDA pre-ESOP margin

Q2 FY2623.9%
Q2 FY2724.2%

https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6c319faf-8b70-4c0b-99a7-4a47186e08db.pdf

CHART 4

Group PAT excluding exceptional gains

Q2 FY26₹305 crore
Q2 FY27₹317 crore

https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6c319faf-8b70-4c0b-99a7-4a47186e08db.pdf

ORIGINAL RESEARCH INSIGHTS

Investment findings and watch points

RESEARCH INSIGHT

Group revenue increased 17.3%

Hospital demand supports scale

Watch: Check PAT conversion

RESEARCH INSIGHT

Pre-ESOP EBITDA grew 19.2%

Not the same as reported EBITDA

Watch: Reconcile ESOP expense

RESEARCH INSIGHT

Pre-ESOP margin improved slightly

ESOP expense remains an economic cost

Watch: Monitor reported margin

RESEARCH INSIGHT

PAT excluding exceptional gains rose 4%

Bottom line lagged revenue growth

Watch: Review funding costs

FULL PUBLISHED RESEARCH

Earnings and management commentary analysis

Fortis Healthcare Limited (NSE: FORTIS) | Q2 FY27 and H1 FY27 | Quarter ended 30 September 2026 | Consolidated results unless expressly labelled hospital or diagnostics

Investment stance: WATCH. Fortis reported ₹2,735 crore of consolidated Q2 revenue, up 17.3%, with hospitals providing the larger growth engine and diagnostics contributing steady expansion. Consolidated profit after tax excluding exceptional gains increased 4.0% to ₹317 crore, slower than revenue. The company's operating EBITDA before employee stock-option expense (pre-ESOP) grew 19.2% to ₹663 crore, a 24.2% margin versus 23.9% a year earlier. This pre-ESOP measure must not be represented as statutory reported EBITDA: management said ESOP expense reduced the reported margin by approximately 1.5 percentage points of revenue. [S1][S2]

Reported/issuer-defined metricQ2 FY26Q2 FY27Accounting scope
Consolidated revenue, ₹ croreApprox. 2,332*2,735Group; prior year implied from rounded 17.3% growth
Consolidated operating EBITDA pre-ESOP, ₹ croreApprox. 556*663Management measure; prior year implied from rounded 19.2% growth
Operating EBITDA pre-ESOP margin, %23.924.2Group management measure
Consolidated PAT excluding exceptional gains, ₹ crore305317Group adjusted for specified gains
Hospital revenue, ₹ crore1,9742,340Hospital business
Hospital occupancy, %7172Hospital business
Hospital ARPP, ₹ lakh1.962.10Gross inpatient revenue definition
Diagnostics gross revenue, ₹ crore400448Diagnostics business

*Implied rounded comparators are explicitly calculations from the company's growth rates, not independently reported absolute prior-year numbers. The remaining figures are directly presented by management. Hospital and diagnostics gross revenue should not be mechanically added to obtain group consolidated revenue because segment reporting and eliminations may differ. [S1][S2]

Six decision takeaways

  • Growth: Consolidated Q2 revenue was ₹2,735 crore, up 17.3%; H1 revenue reached ₹5,280 crore, up 17.4%. [S2]
  • Hospital engine: Hospital Q2 revenue rose to ₹2,340 crore from ₹1,974 crore, an 18.6% increase. [S2]
  • Patient economics: Occupancy improved to 72% from 71%, and average revenue per inpatient patient (ARPP) increased 6.8% to ₹2.10 lakh from ₹1.96 lakh. [S1][S2]
  • Operating profitability: Group pre-ESOP EBITDA increased to ₹663 crore, with margin at 24.2%; the ESOP exclusion is material and must be disclosed. [S1]
  • Diagnostics: Gross diagnostics revenue grew to ₹448 crore from ₹400 crore, with a PAT margin on gross revenue of 15.2% versus 14.8%. [S2]
  • Leverage: Consolidated net debt stood at ₹2,188 crore on 30 September 2026; management's net-debt-to-EBITDA ratio was 0.87x, calculated on annualised Q2 EBITDA, versus 0.96x a year earlier. [S1][S2]

Decision threshold: The evidence supports hospital revenue growth and modest occupancy improvement, but the valuation case requires a clear bridge from pre-ESOP EBITDA to reported earnings and cash generation, alongside disciplined returns on acquisitions and new beds. No current share price or fair-value target is supplied by the selected sources, so none is invented.

Chapter 1 — Investor decision: hospital operating leverage versus capital intensity

Fortis is a multispecialty hospital operator with an associated diagnostics platform, Agilus Diagnostics. Its economic drivers differ: hospitals require land, buildings, medical equipment, specialist clinicians, bed utilisation and high-acuity case mix; diagnostics require laboratory networks, sample throughput, pricing discipline and customer retention. A consolidated revenue growth rate does not reveal which business is creating incremental returns. [S1][S2]

The hospital business is currently the stronger revenue-growth engine. Its Q2 revenue increased 18.6%, supported by both higher occupancy and improved revenue per inpatient. Management reported 3,616 occupied beds versus 3,318 a year earlier, a 9% increase. That expansion in occupied beds exceeds the one-percentage-point improvement in reported occupancy, indicating that the operational bed base and activity level also matter. It would be misleading to attribute the entire revenue increase to price or case mix. [S1]

Management reported 15 hospital facilities with operating EBITDA margin above 20%, accounting for about 84% of hospital revenue, compared with 13 facilities contributing 76% in the previous comparison period. This suggests greater concentration of revenue in relatively profitable facilities, but the comparison does not disclose each hospital's capital employed or mature-versus-ramping status. It is therefore a useful quality signal, not a complete return-on-capital measure. [S1]

Fortis described 6,300-plus operational beds, with a broader network of doctors and nurses. Its expansion pipeline is material; management discussed approximately 2,000 beds already contracted or in the visible expansion pipeline, with additional acquisitions and greenfield projects potentially increasing the number. These are planned or contracted beds, not beds already operational and earning full mature margins. [S1][S2]

Decision tests

  • Track occupied beds, occupancy and ARPP together to separate capacity, utilisation and revenue intensity. [S1]
  • Compare hospital-level margins with commissioning age and capital invested, not only group pre-ESOP EBITDA. [S1]
  • Evaluate diagnostics on gross revenue and its separately defined PAT margin, not on hospital operating margin. [S2]
  • Treat the 2,000-bed expansion pipeline as an execution commitment, not current revenue. [S1]

Chapter 2 — Q2/H1 results and the earnings-quality bridge

The investor presentation reports ₹2,735 crore consolidated Q2 revenue, up 17.3% year on year. Consolidated PBT excluding exceptional items was ₹429 crore, up 6.8%, while consolidated PAT on the same stated exclusion basis was ₹317 crore, up 4.0%. The slower bottom-line growth compared with revenue matters: expansion and operating profit do not automatically produce proportional shareholder earnings. [S2]

For H1 FY27, consolidated revenue was ₹5,280 crore, up 17.4%; PBT excluding exceptional items was ₹783 crore, up 5.8%; and PAT excluding exceptional items was ₹581 crore, up 3.8%. The corresponding H1 PAT margin was 11.0%, while the Q2 adjusted PAT margin was 11.6%. The differences in growth rates should be examined through depreciation, finance costs, tax and business mix, rather than inferred from revenue alone. [S2]

Management's earnings call disclosed consolidated operating EBITDA pre-ESOP of ₹663 crore, up 19.2%, and a 24.2% margin compared with 23.9% in Q2 FY26. The CFO said the ESOP expense represented approximately 1.5% of revenue and that the pre-ESOP presentation was chosen because the expense was non-cash and the scheme was introduced after the budget exercise. Non-cash compensation is still an economic cost to shareholders. Investors should not treat a pre-ESOP margin as the same as reported EBITDA or ignore dilution. [S1]

The hospital business reported operating EBITDA of ₹545 crore, with margin 23.3% versus 22.9% a year earlier. The diagnostics business operating EBITDA margin was 26.2%, versus 26.1%. These operating metrics are business-specific and cannot be substituted for consolidated reported EBITDA without segment reconciliation. [S1]

Exceptional items also matter. The hospital business PAT cited in the presentation excludes exceptional gains of ₹3 crore in Q2 FY27 and ₹24 crore in Q2 FY26, principally related to reversal of impairment in an associate. The adjusted hospital PAT was ₹281 crore, up 6.6%, while the adjusted hospital PAT margin declined to 12.0% from 13.4%. This is a specific, disclosed adjustment; no additional normalisations are fabricated. [S2]

Earnings-quality checks

  • Keep pre-ESOP and reported EBITDA distinct and track the ESOP cost and dilution. [S1]
  • Compare PAT after the same exceptional-item exclusions in both periods. [S2]
  • Do not add hospital and diagnostics operating EBITDA to an assumed group total without eliminations. [S1]
  • Monitor whether hospital revenue growth converts into adjusted PAT margin recovery. [S2]

Chapter 3 — Hospital economics, clinical mix and diagnostics

Hospital revenue increased to ₹2,340 crore from ₹1,974 crore. Management attributed growth to activity and clinical performance, while disclosing occupancy of 72% against 71% and ARPP of ₹2.10 lakh versus ₹1.96 lakh. ARPP is defined using gross inpatient revenue, excluding specified daycare procedures such as chemotherapy, radiotherapy and dialysis. It is not the same as average revenue per occupied bed per day, so it should not be compared with ARPOB figures from other hospitals without adjustment. [S1][S2]

Management said renal sciences, neurosciences and orthopaedics generated year-on-year revenue growth of 27%, 28% and 30%, respectively. Higher-acuity specialties can improve revenue intensity, but they also require investment in specialists, equipment and quality systems. The company reported international business revenue of approximately ₹190 crore, up 12.4%, representing around 8% of hospital revenue. International patient flows provide diversification but are exposed to travel, referral and geopolitical factors. [S1]

The diagnostics platform reported ₹448 crore gross Q2 revenue, compared with ₹400 crore a year earlier, an increase of 12.2%. Its PAT margin on gross revenue was 15.2%, up from 14.8%. Management also reported a modest operating EBITDA-margin improvement to 26.2% from 26.1%. Diagnostics therefore appears to have a steadier margin trend than the more capital-intensive hospital expansion programme, but gross-revenue and consolidated-net-revenue bases must be kept separate. [S1][S2]

Hospital occupancy alone is not enough to value a bed. A new hospital can add beds faster than occupied beds, depressing early utilisation; a mature facility may raise revenue through specialty mix while occupancy remains flat. Fortis's disclosed increase in occupied beds and ARPP is more informative than either figure separately. Investors should ask for same-hospital growth, ramp-up cohorts and capital employed by facility before projecting future margins.

Operating takeaways

  • The 9% growth in occupied beds and 6.8% increase in ARPP both support hospital revenue expansion. [S1]
  • High-growth specialties should be tracked alongside clinician retention and equipment productivity. [S1]
  • Diagnostics gross revenue growth and PAT margin should be assessed on their own definitions. [S2]
  • International revenue adds opportunity but should not be projected without referral and payer data. [S1]

Chapter 4 — Management execution, hospital acquisitions and analyst questions

Management's visible expansion plan includes roughly 2,000 beds in contracted or existing pipeline projects, while actively considering further acquisitions and greenfield developments. The CFO explained that this visible pipeline did not capture every potential project and that the number could rise over three to four years. Investors should distinguish a pipeline that is under contract from speculative future acquisition opportunities. [S1]

An analyst asked about return hurdles and payback periods for acquisitions. Management stated that the board-approved internal framework generally does not consider projects with an IRR below 15% or a payback exceeding eight to ten years, while acknowledging that strategic considerations can sometimes influence decisions. This is an internal hurdle and management statement, not independently verified realised project IRR. It provides a useful benchmark for future acquisition accountability. [S1]

The CFO was also questioned about EBITDA reporting before ESOP expense. He said the expense was non-cash and that the presentation convention reflected the scheme's timing, while acknowledging a roughly 1.5-percentage-point revenue impact on reported EBITDA. That exchange is important because institutional investors should assess both operating cash generation and equity dilution. A non-cash expense can still transfer economic value to employees. [S1]

Expansion must be evaluated against a facility's development cycle. Beds that are acquired, newly constructed, staffed, commissioned and mature carry different occupancy and profit expectations. The company reported an improved mix of facilities above a 20% operating EBITDA margin, but the aggregate does not reveal the capital intensity of newly added beds. A disciplined investor should demand actual post-opening performance rather than simply counting planned beds. [S1]

Execution milestones

  • Track contracted and commissioned beds separately from management's broader opportunity pipeline. [S1]
  • Compare new acquisition returns with the stated 15% IRR and eight-to-ten-year payback framework. [S1]
  • Monitor facility-level occupancy, ARPP, specialist mix and EBITDA after opening. [S1]
  • Include ESOP cost when evaluating reported margins and per-share economics. [S1]

Chapter 5 — Net debt, capex and returns on invested beds

Fortis disclosed ₹2,188 crore of consolidated net debt at 30 September 2026. Its net-debt-to-EBITDA ratio was 0.87x, compared with 0.96x in the year-earlier comparison. Importantly, the presentation specifies that this leverage ratio uses Q2 annualised EBITDA, rather than a conventional trailing-twelve-month EBITDA calculation. An analyst should not compare the 0.87x directly with peers' TTM ratios without adjusting the denominator. [S1][S2]

The group's current expansion strategy makes cash allocation especially important. Hospital acquisitions can increase the operational bed base rapidly but may bring integration costs, capital commitments and working-capital needs. Greenfield hospitals can require years of construction, commissioning and occupancy ramp before mature cash generation. The visible 2,000-bed pipeline is therefore a future capital requirement, not immediately available earnings capacity. [S1]

The selected sources do not establish a complete statutory cash-flow and acquisition-capex bridge sufficient to calculate group free cash flow after all investment spending. This report does not invent a cash conversion ratio or assume that pre-ESOP EBITDA can fund all expansion. The useful monitoring items are cash generated from operations, maintenance and growth capex, acquisition consideration, net debt, leases and the proportion of facilities reaching mature margins. [S1][S2]

Management's stated hurdle of at least 15% IRR for typical projects and payback not exceeding eight to ten years offers a practical test, but it is not a substitute for observed returns. Investors should evaluate the realised post-tax return on invested capital at each acquired or greenfield facility, taking into account the time needed to reach stable occupancy. A nominally attractive bed count can destroy value if its operating cash flow never earns the cost of capital.

Capital-allocation checks

  • Reconcile net debt and leverage to the disclosed annualised-quarter EBITDA denominator. [S2]
  • Require actual cash capex and acquisition consideration before projecting free cash flow.
  • Separate contracted beds from commissioned and occupied beds. [S1]
  • Compare realised acquisition returns with management's stated IRR and payback hurdles. [S1]

Chapter 6 — Conditional bull, base and bear cases

Bull case — hospital scale converts into cash returns. Occupancy holds above the Q2 72% level, ARPP benefits from higher-acuity case mix, and newly added facilities reach mature utilisation without excessive funding costs. Diagnostics continues growing gross revenue with stable margins. Reported EBITDA after ESOP and adjusted PAT both rise alongside cash generation, while net debt remains controlled. This case requires observed margins and cash flows, not only planned beds. [S1][S2]

Base case — healthy demand but measured earnings conversion. Hospital revenue continues growing from a larger bed base, while new facilities incur commissioning costs and the ESOP scheme remains a visible adjustment. Diagnostics contributes steady growth, but consolidated PAT rises more slowly than revenue. Net debt remains manageable on the company's annualised-quarter leverage basis, though acquisitions and construction require careful phasing. This is a conditional narrative, not a numerical forecast.

Bear case — expansion outruns returns. New hospitals take longer to fill, clinical recruitment and equipment costs rise, ARPP growth slows, and acquisitions fail to achieve management's stated return hurdles. ESOP costs and depreciation suppress reported earnings even as pre-ESOP EBITDA remains optically strong. Debt could rise if cash generation falls short of acquisition and construction spending. The risk is weaker per-share cash returns, not a fabricated share-price target.

Falsifiers

  • Occupancy and occupied-bed growth fail to keep pace with newly commissioned capacity. [S1]
  • ARPP growth slows materially from the disclosed 6.8% while high-acuity case mix becomes less favourable. [S1]
  • The gap between pre-ESOP operating EBITDA and reported EBITDA remains material without a clear per-share benefit. [S1]
  • Diagnostics margins weaken while gross revenue continues to grow. [S2]
  • Net leverage rises materially despite management's expansion-return framework. [S1][S2]

Chapter 7 — Investor action plan and quarterly monitoring

Action: WATCH, with priority on reported earnings conversion and realised returns from hospital expansion. The quarter shows real hospital activity growth and steady diagnostics margins. The main valuation risks are adjustment-heavy EBITDA presentation, the time required to ramp new beds and the financing of acquisitions.

Monitoring itemQ2 FY27 referenceDecision test
Consolidated revenue₹2,735 croreDoes growth reach reported PAT and cash?
Consolidated PAT excluding exceptional gains₹317 croreDoes growth accelerate beyond 4%?
Group operating EBITDA pre-ESOP₹663 croreWhat is reported EBITDA after ESOP?
Hospital revenue₹2,340 croreSame-hospital versus acquired growth?
Hospital occupancy72%Are new beds filling sustainably?
Occupied beds3,616Is patient throughput rising?
Hospital ARPP₹2.10 lakhIs specialty mix improving?
Hospital operating EBITDA margin23.3%Are mature and ramping facilities differentiated?
Diagnostics gross revenue₹448 croreIs growth profitable and cash-generative?
Diagnostics PAT margin15.2%Is margin maintained?
Consolidated net debt₹2,188 croreHow is expansion funded?
Net-debt/annualised-Q2 EBITDA0.87xCompare using a consistent denominator
Visible expansion pipeline~2,000 bedsHow many are commissioned and occupied?

Next-quarter investor checklist

  • Compare occupancy and ARPP on the same hospital basis, with mature-versus-new facility detail. [S1]
  • Reconcile pre-ESOP EBITDA to reported EBITDA and evaluate the dilution effect. [S1]
  • Track adjusted PAT and disclose exceptional items separately, as in the current quarter. [S2]
  • Monitor hospital specialties and international patient mix for durable pricing power. [S1]
  • Evaluate diagnostics revenue and PAT margin on the gross-revenue basis used by the company. [S2]
  • Reconcile net debt, acquisition consideration and cash capex to actual cash-flow statements. [S1][S2]
  • Test realised acquisition IRRs against the stated 15% hurdle and payback framework. [S1]

Specific evidence limitations: The cited presentation and transcript do not provide a complete acquisition-by-acquisition invested-capital and cash-flow bridge, current share valuation or independently reconciled reported-versus-pre-ESOP group EBITDA series. The issuer's 0.87x leverage measure annualises Q2 EBITDA, and the company's expansion targets and internal IRR hurdles are not realised historical returns. No unsupported cash-flow, price-target or project-return figures are supplied.

Original issuer/exchange filings

Amounts are in ₹ crore unless otherwise indicated. Group, hospital, diagnostics, pre-ESOP, reported and adjusted figures are labelled separately.

Additional company evidence

CHART 5

Hospital revenue

Q2 FY26₹1,974 crore
Q2 FY27₹2,340 crore

https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6c319faf-8b70-4c0b-99a7-4a47186e08db.pdf

CHART 6

Hospital occupancy

Q2 FY2671%
Q2 FY2772%

https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6c319faf-8b70-4c0b-99a7-4a47186e08db.pdf

CHART 7

Hospital occupied beds

Q2 FY263,318 Beds
Q2 FY273,616 Beds

https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6c319faf-8b70-4c0b-99a7-4a47186e08db.pdf

CHART 8

Hospital ARPP

Q2 FY26₹1.96 lakh
Q2 FY27₹2.1 lakh

https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6c319faf-8b70-4c0b-99a7-4a47186e08db.pdf

SOURCE REFERENCES

Original disclosures and investor presentations

  1. Issuer disclosure
  2. Issuer disclosure

Related research and comparisons

Other published Q2 FY27 reports

This is dated research, not a live market quote. Scenarios and historical performance are not guarantees.